Abstract
Background: Patients with chronic kidney disease (CKD) suffer increased morbidity and mortality from cardiovascular diseases (CVD). Asymmetric dimethylarginine (ADMA), an endogenous endothelial nitric oxide synthase (eNOS) inhibitor, is elevated in CKD. ADMA has been suggested to increase CVD in CKD, but direct evidence is missing. We assessed the effect of ADMA in endothelial function in CKD. Methods and Results: We created a CKD model by performing 5/6 nephrectomy (Nx) in mice. Samples were collected for measurements of renal function and ADMA, and NOx levels at 4 weeks after Nx.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
